Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and diagnostics, reported that a second milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics, a joint venture to develop next-gen cell therapies between Avacta and Daewoong Pharmaceutical based in South Korea. Avacta has successfully developed and characterized Affimer proteins against the second target of interest for AffyXell and has file...